Multiple Myeloma Education Platform for Myeloma community by Dr. Malik and team. Data Driven Individualized Treatments for every patient - Pathway towards cure
Afshan Malik MD is a certified oncologist in New York City with focus on Multiple Myeloma.
10/19/2022
NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
https://www.themyelomaclinicaltrials.com/single-post/isb1442-ichnos
https://www.themyelomaclinicaltrials.com/rrmm
10/19/2022
Recruiting: NCT05027594: Phase 1: Study of NMS-03597812, a PERK Inhibitor in Adult Pts With Relapsed or Refractory Myeloma
https://www.themyelomaclinicaltrials.com/single-post/nms-03597812
https://www.themyelomaclinicaltrials.com/rrmm
09/29/2022
NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma just published in NEJM
https://tinyurl.com/3f5j5syf
09/13/2022
NCT04566328: Phase 3 - Testing the Use of Combination Therapy in NDMM, the EQUATE Trial - EAA181 https://www.themyelomaclinicaltrials.com/single-post/equate
06/13/2022
Data Driven Individualized Treatments for every patient - Pathway towards cure
IMWG Conference Series, “Making Sense of Treatment” on June 16. Leading myeloma experts will discuss the latest drug therapy news from the American Society of Clinical Oncology (ASCO) conference, IMF IMWG Summit, and the European Hematology Association (EHA) Annual Conference. https://bit.ly/3tyk0yh
05/11/2022
You just can't beat the person who won't give up -Babe Ruth
Multiple Myeloma Clinical Trials Multiple Myeloma Clinical Trials info and Multiple Myeloma Education Platform for Patients and Families.
05/03/2022
04/27/2022
This video comes from a lady who wants to know about mass spectrometry. She's heard this phrase and she wants to know: "Is this a test that I should be aware of?"
https://www.myeloma.org/blog/future-myeloma-care
04/26/2022
Revlimid (lenalidomide) is an immunomodulatory agent for treatment of Multiple Myeloma. Here are some of the common things to watch out for while receiving this treatment. Learn more about it’s possible side effects and management in drug section of the website by visiting www.mmeducation.org
Multiple Myeloma Clinical Trials Multiple Myeloma Clinical Trials info and Multiple Myeloma Education Platform for Patients and Families.
04/26/2022
Revlimid (lenalidomide) is an immunomodulatory agent for treatment of Multiple Myeloma. Here are some of the common things to watch out for while receiving this treatment. Learn more about it’s possible side effects and management in drug section of the website by visiting www.mmeducation.org
| Monday | 8am - 5pm |
| Tuesday | 8am - 5pm |
| Wednesday | 8am - 5pm |
| Thursday | 8am - 5pm |
| Friday | 8am - 5pm |